Riskpilot← Back to searchSign inGet full accessVisiopharm LRI AB
ABActiveOrg 5566989454Dag Hammarskjölds Väg 1 AWholesale of pharmaceutical and medical goods · NACE 4646Est. 20063 employees
Revenue 2025
SEK 43,1M
+24% vs 2024
EBITDA margin
6.2%
-6% vs 2024
Equity ratio
48.9%
Financial strength
Net profit 2025
SEK 2,2M
-14% vs 2024
| Revenue | SEK 43,1M | +24% |
| EBITDA | SEK 2,7M | -6% |
| Net profit | SEK 2,2M | -14% |
| Total assets | SEK 30,1M | +8% |
| Equity | SEK 14,7M | +18% |
| Employees | 3 | — |
Legal name
Visiopharm LRI AB
Org number
5566989454
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2 mars 2006
Share capital
SEK 100 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att bedriva försäljning av mjuk- och hårdvara för bildhantering och bildanalys till företag, sjukhus samt universitet samt därmed förenlig verksamhet.
Address
Dag Hammarskjölds Väg 1 A
Phone
+4646133591
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 29 264 | 24 999 | 20 531 | 34 801 | 43 057 |
| Staff expenses | — | — | — | — | −4 783 |
| EBITDA | 2 059 | 2 358 | 750 | 2 819 | 2 651 |
| Depreciation & amort. | −0 | −0 | −6 | −7 | −7 |
| EBIT | 2 059 | 2 358 | 744 | 2 812 | 2 645 |
| Net financials | −3 | −1 | 138 | 443 | 163 |
| Profit before tax | 2 056 | 2 357 | 883 | 3 255 | 2 808 |
| Tax | −444 | −510 | −198 | −681 | 598 |
| Net profit | 1 612 | 1 847 | 685 | 2 574 | 2 210 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 11 831 | 15 517 | 20 314 | 27 851 | 30 063 |
| Equity | 7 388 | 9 235 | 9 920 | 12 494 | 14 704 |
| Long-term debt | 96 | 463 | 261 | 561 | 376 |
| Short-term debt | 4 347 | 5 819 | 10 133 | 14 796 | 14 982 |
| Total debt | 4 443 | 6 282 | 10 394 | 15 357 | 15 359 |
EBITDA margin
6.2%
This company
15.8%
Market median
-61% vs market
20212025
Equity ratio
48.9%
This company
38.2%
Market median
+28% vs market
20212025
Return on equity
15.0%
This company
18.4%
Market median
+18% vs market
20212025
Net profit margin
5.1%
This company
8.1%
Market median
-37% vs market
20212025
Asset turnover
1.43×
This company
1.12×
Market median
+28% vs market
20212025
Debt / equity
1.04×
This company
0.62×
Market median
-68% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
PM Chief Auditor | Chief Auditor | 2022 |
PA Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
MR Audit | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VISIOPHARM A/S
Visiopharm LRI AB (this company)Board members of Visiopharm LRI AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Paul Mikael Åke Hansson | Chief Auditor | 0 companies |
| Per Arne Rickard Lindelöf | Chief Executive Officer | 0 companies |
| Magnus Rolf Hahnsjö | Audit | 0 companies |
| Johan Doré Hansen | Deputy Board Member | 0 companies |
| Poul Kristian Dalhof Nielsen | Chairman | 0 companies |
| Michael Grunkin | Board of Directors | 0 companies |